| Expression pattern: |
UP |
| Associated gene: |
LMO4, Ago2 |
| Associated microRNA: |
miR-637 |
| Biological function: |
promotes PTC cell proliferation, migration and invasion; inhibits apoptosis; promotes tumor growth in vivo |
| Molecular mechanism: |
ceRNA mechanism: circLDLR sponges miR-637 to indirectly upregulate LMO4 |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; Western Blot; In Vivo Animal Model |
| Clinical significance: |
Higher circLDLR expression was correlated with advanced TNM stages, tumor size, and lymph node metastasis; high circLDLR predicted shorter overall survival in PTC patients. |
| Description: |
circLDLR is up-regulated in papillary thyroid carcinoma tissues and cell lines and is mainly localized in the cytoplasm. It promotes PTC malignant phenotypes and tumor growth by sponging miR-637 to relieve repression of LMO4 (circLDLR/miR-637/LMO4 ceRNA axis), and high circLDLR expression is associated with poorer overall survival. |
| Confidence score: |
0.8354 |